Egenesis Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 54
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $100M
Latest Deal Amount
  • Investors
  • 14

Egenesis General Information

Description

Developer of a gene transplantation platform designed to address the global organ crisis. The company's platform performs gene editing and genome engineering to provide an alternative source of safe and effective human-compatible organs, enabling patients with end-stage organ disease to recover and lead a healthy life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 300 Technology Square
  • Suite 301
  • Cambridge, MA 02139
  • United States

Egenesis Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Egenesis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 01-Nov-2019 $100M 00000 00000 Completed Generating Revenue
3. Later Stage VC (Series A3) 02-Aug-2019 0000 Completed Generating Revenue
2. Early Stage VC (Series A2) 18-Jun-2018 $38M Completed Generating Revenue
1. Early Stage VC (Series A1) 13-Mar-2017 $38M $38M 000.00 Completed Generating Revenue
To view Egenesis’s complete valuation and funding history, request access »

Egenesis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
To view Egenesis’s complete cap table history, request access »

Egenesis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a gene transplantation platform designed to address the global organ crisis. The company's platform perform
Biotechnology
Cambridge, MA
54 As of 2020
00000
0000 0000-00-00
00000000000 00000

00000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cul
0000000000000
Mountain View, CA
00 As of 0000
000000000 -

0000000

sum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolor
0000000000000
Beijing, China
000 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Egenesis Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cellecta Private Debt Financed Mountain View, CA 00 000000000 -
0000000 Venture Capital-Backed Beijing, China 000 00000 00000000000 00000
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
00000000 000000000 Formerly VC-backed Cambridge, MA 000 0000 000000 - 000 0000
00000000 000000000 Formerly VC-backed Bedford, MA 000 00000 00000000 00000
You’re viewing 5 of 27 competitors. Get the full list »

Egenesis Executive Team (12)

Name Title Board Seat Contact Info
Michael Curtis Ph.D President, Research & Development
Peter Hanson Ph.D Chief Operating Officer
Luhan Yang Ph.D Co-Founder, Board Member & Co-Chief Scientific Officer
Ariel Jasie JD Chief Business Officer & General Counsel
William Westlin Ph.D Co-Chief Scientific Officer
You’re viewing 5 of 12 executive team members. Get the full list »

Egenesis Board Members (10)

Name Representing Role Since
Albert Wiegman II Fresenius Medical Care Ventures Board Member 000 0000
Bob More Self Board Member 000 0000
Boris Nikolic MD Biomatics Capital Board Member 000 0000
Daniel Lynch Self Executive Chairman 000 0000
Julie Sunderland Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Egenesis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Egenesis Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fresenius Medical Care Ventures Corporate Venture Capital Minority 000 0000 000000 0
Leaps by Bayer Corporate Venture Capital Minority 000 0000 000000 0
Wellington Partners Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Alta Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Egenesis Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 20-May-2020 000000000000000000 Drug Discovery 0000 000000
To view Egenesis’s complete acquisitions history, request access »